Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
The nNOS - PSD-95 Interaction Inhibitor, ZL006 controls the biological activity of nNOS. This small molecule/inhibitor is primarily used for Cancer applications.
More>>The nNOS - PSD-95 Interaction Inhibitor, ZL006 controls the biological activity of nNOS. This small molecule/inhibitor is primarily used for Cancer applications. Less<<
MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neurons (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment) in vitro and in mice (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before ischemia; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents). Effectively reduce ischemia-caused brain tissue damage in both mice and rats when applied 1 h after blood reperfusion following ishemia (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neuron cultures (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment before 30 min Glu-Gly stimulation) in vitro and in mice subjected to middle brain artery occlusion (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before MACO; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents) in rat hippocampus. Its therapeutic efficacy in limiting ischemia-caused brain tissue damage has been demonstrated in both mice and rats when applied 1 h after blood reperfusion following MACO (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).
Form
Off-white solid
Intert gas (Yes/No)
Packaged under inert gas
Chemical formula
C₁₄H₁₁Cl₂NO₄
Structure formula
Purity
≥98% by HPLC
Solubility
DMSO (50 mg/ml)
Storage
Protect from light
-20°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
